Trung Huynh
Stock Analyst at RBC Capital
(4.53)
# 240
Out of 5,179 analysts
62
Total ratings
60.47%
Success rate
21.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underperform | $25 | $27.04 | -7.54% | 7 | Feb 25, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $878.24 | +42.33% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $58.54 | +2.49% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $209.40 | +24.16% | 2 | Feb 25, 2026 | |
| MRK Merck & Co. | Initiates: Outperform | $142 | $119.63 | +18.70% | 5 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $737.71 | -10.53% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $145.30 | +53.48% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.05 | +2,280.95% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $348.77 | -9.11% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $30.30 | +25.41% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $2.68 | +161.19% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.80 | +66.67% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $240.45 | -27.22% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.49 | - | 1 | Mar 23, 2021 |
Pfizer
Feb 25, 2026
Initiates: Underperform
Price Target: $25
Current: $27.04
Upside: -7.54%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $878.24
Upside: +42.33%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $58.54
Upside: +2.49%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $209.40
Upside: +24.16%
Merck & Co.
Feb 25, 2026
Initiates: Outperform
Price Target: $142
Current: $119.63
Upside: +18.70%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $737.71
Upside: -10.53%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $145.30
Upside: +53.48%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.05
Upside: +2,280.95%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $348.77
Upside: -9.11%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $30.30
Upside: +25.41%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.68
Upside: +161.19%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.80
Upside: +66.67%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $240.45
Upside: -27.22%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $7.49
Upside: -